Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | EDNRA | P25101 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | PPARG | P37231 | 14/20 | 0.80 |
| ▸ | RXRA | P19793 | 6/20 | 0.74 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.71 |
| ▸ | EGFR | P00533 | 1/20 | 0.71 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.71 |
| ▸ | DRD1 | P21728 | 1/20 | 0.71 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.71 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Exisulind SCHEMBL1651133 | 1.00 | CYP1A2 (1.00) | CYP1A2MAPTMAPK1TDP1CYP3A4 | |
| Exisulind SCHEMBL29395528 | 1.00 | CYP1A2 (1.00) | CYP1A2MAPTMAPK1TDP1CYP3A4 | |
| Exisulind SCHEMBL4776597 | 1.00 | CYP1A2 (1.00) | CYP1A2MAPTMAPK1TDP1CYP3A4 | |
| Exisulind SCHEMBL9711060 | 0.99 | CYP1A2 (0.98) | CYP1A2MAPTMAPK1TDP1CYP3A4 | |
| Exisulind SCHEMBL7634644 | 0.99 | CYP1A2 (0.98) | CYP1A2MAPTMAPK1TDP1CYP3A4 | |
| SCHEMBL24101477 | 0.91 | PPARG (0.84) | CYP1A2MAPTMAPK1TDP1CYP3A4 | |
| SCHEMBL30095195 | 0.91 | PPARG (0.84) | CYP1A2MAPTMAPK1TDP1CYP3A4 | |
| SCHEMBL20158513 | 0.91 | CYP1A2 (0.83) | CYP1A2MAPTMAPK1TDP1CYP3A4 | |
| Exisulind SCHEMBL7634637 | 0.91 | CYP1A2 (0.83) | CYP1A2MAPTMAPK1TDP1CYP3A4 | |
| Exisulind SCHEMBL7634632 | 0.91 | CYP1A2 (0.83) | CYP1A2MAPTMAPK1TDP1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6367 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12465605-B2 | Methods and materials for gender-dependent treatment of cardiovascular dysfunction | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2025-11-11 | — | — | US | claimed |
| WO-2023075715-A1 | A PHARMACEUTICAL FORMULATION INCLUDING LEUKOTRIENE RECEPTOR ANTAGONISTS AND/OR LEUKOTRIENE SYNTHESIS INHIBITORS COMBINED WITH NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) | VSY BIYOTEKNOLOJI VE ILAC SANAYI ANONIM SIRKETI (TR) | 2023-05-04 | — | — | WO | claimed |
| US-20210154200-A1 | 7-BENZYL-4-(METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZO[1,2-A]PYRIDO[3,4-E]PYRIMIDIN-5 (1H)-ONE, SALTS THEREOF AND METHODS OF USING THE SAME IN COMBINATION THERAPY | ONCOCEUTICS, INC. (US) | 2021-05-27 | — | — | US | claimed |
| US-20210052591-A1 | LIQUID ORAL FORMULATIONS FOR PDE V INHIBITORS | LIQMEDS WORLDWIDE LIMITED (GB) | 2021-02-25 | — | — | US | claimed |
| EP-3731870-A1 | LIQUID ORAL FORMULATIONS FOR PDE V INHIBITORS | FTF Pharma Private Limited (IN) | 2020-11-04 | — | — | EP | claimed |
| EP-2900236-B1 | TREATMENT OF WOLFRAM SYNDROME-RELATED NEURODEGENERATION | UNIV BIRMINGHAM (GB) | 2019-01-16 | — | — | EP | claimed |
| US-10124038-B2 | Modulators of syndecan-2 and uses thereof | ORBSEN THERAPEUTICS LIMITED (IE) | 2018-11-13 | — | — | US | claimed |
| EP-3271396-A1 | MODULATORS OF SYNDECAN-2 AND USES THEREOF | Orbsen Therapeutics Limited (IE) | 2018-01-24 | — | — | EP | claimed |
| EP-2477699-B1 | MEDICAL USE OF SPLA2 HYDROLYSABLE LIPOSOMES | BIO-BEDST APS (DK) | 2017-11-08 | — | — | EP | claimed |
| US-9629855-B2 | Pharmaceutical composition for treatment of eye pain, containing PGE2 synthesis inhibitor | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2017-04-25 | — | — | US | claimed |
| US-6235776-B1 | ADMINISTERING WITH PHOSPHODIESTERASE INHIBITOR | CELL PATHWAYS, INC. | 2001-05-22 | — | — | US | claimed |
| WO-2000027194-A9 | METHOD FOR TREATING A PATIENT WITH NEOPLASIA BY TREATMENT WITH A PACLITAXEL DERIVATIVE | CELL PATHWAYS INC (US) | 2000-11-23 | — | — | WO | claimed |
| WO-2000027193-A9 | METHOD FOR TREATING A PATIENT WITH NEOPLASIA BY TREATMENT WITH A GONADOTROPIN RELEASING HORMONE ANALOG | CELL PATHWAYS INC (US) | 2000-09-21 | — | — | WO | claimed |
| WO-2000027403-B1 | METHOD FOR TREATING A PATIENT WITH NEOPLASIA BY TREATMENT WITH A PYRIMIDINE ANALOG | CELL PATHWAYS INC (US) | 2000-07-06 | — | — | WO | claimed |
| WO-2000027404-A1 | METHOD FOR TREATING A PATIENT WITH NEOPLASIA BY TREATMENT WITH AN ANTHRACYCLINE ANTIBIOTIC | CELL PATHWAYS, INC. (US) | 2000-05-18 | — | — | WO | claimed |
| WO-2000027194-A1 | METHOD FOR TREATING A PATIENT WITH NEOPLASIA BY TREATMENT WITH A PACLITAXEL DERIVATIVE | CELL PATHWAYS, INC. (US) | 2000-05-18 | — | — | WO | claimed |
| WO-2000027391-A1 | METHOD FOR TREATING A PATIENT WITH NEOPLASIA BY TREATMENT WITH A PLATINUM COORDINATION COMPLEX | CELL PATHWAYS, INC. (US) | 2000-05-18 | — | — | WO | claimed |
| WO-2000027193-A1 | METHOD FOR TREATING A PATIENT WITH NEOPLASIA BY TREATMENT WITH A GONADOTROPIN RELEASING HORMONE ANALOG | CELL PATHWAYS, INC. (US) | 2000-05-18 | — | — | WO | claimed |
| WO-2000027403-A1 | METHOD FOR TREATING A PATIENT WITH NEOPLASIA BY TREATMENT WITH A PYRIMIDINE ANALOG | CELL PATHWAYS, INC. (US) | 2000-05-18 | — | — | WO | claimed |
| US-4423075-A | Aldose reductase inhibition by 5-fluoro-2-methyl-1-[[4-(methylsulfonyl)phenyl]methylene]-1H-indene-3-acetic acid | AYERST, MCKENNA & HARRISON INC. (CA) | 1983-12-27 | — | — | US | claimed |